(以下内容从爱建证券《医药行业跟踪报告:MNC重金加码中国创新药,中国IO2.0双抗出海迈出关键一步》研报附件原文摘录)投资要点:医药板块行情复盘:本周(1/26~2/1)市场以震荡调整为主,SW医药生物指数下跌3.31%,在申万一级行业指数中排名22/31,跑输沪深300指数(+0.08%);各细分板块中,血液制品(-0.99%)、疫苗(-1.65%)表现相对较好,主要与尼帕病毒概念相关,部分...
Source Link(以下内容从爱建证券《医药行业跟踪报告:MNC重金加码中国创新药,中国IO2.0双抗出海迈出关键一步》研报附件原文摘录)投资要点:医药板块行情复盘:本周(1/26~2/1)市场以震荡调整为主,SW医药生物指数下跌3.31%,在申万一级行业指数中排名22/31,跑输沪深300指数(+0.08%);各细分板块中,血液制品(-0.99%)、疫苗(-1.65%)表现相对较好,主要与尼帕病毒概念相关,部分...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.